Business Wire

FL-GEG

9.7.2021 19:10:10 CEST | Business Wire | Press release

Share
Global Equestrian Group, Waterland Private Equity, and Wellington Equestrian Partners Join Forces to Invest in the Globalization of Equestrian Sport

Andreas Helgstrand, CEO of Global Equestrian Group (GEG), and Mark Bellissimo, CEO of Wellington Equestrian Partners (WEP), announced an unprecedented partnership focused on developing international equestrian sport. GEG will acquire the Wellington, Florida-based Palm Beach International Equestrian Center (PBIEC) and will invest in WEP equestrian lifestyle initiatives. WEP’s largest partners, Mark Bellissimo, Roger Smith, Lisa Lourie, and Marsha Dammerman as well as Michael Stone will co-invest in GEG. Mark Bellissimo and PBIEC have transformed Wellington into the world’s premiere destination for equestrian enthusiasts, with competitions and events across more than 40 weeks every year. PBIEC is home to the Winter Equestrian Festival, spanning 13 weeks and is the world’s largest and longest-running equestrian sports event. 4,000 families, 8,000 horses, and 250,000 spectators from 43 different countries converge on Wellington to compete for over USD 12 million in prize money. A recent independent economic study highlighted the Winter Equestrian Festival’s annual economic impact on Palm Beach County of USD 279 million of total expenditures and 150,000 bed nights. GEG is part of Waterland Private Equity, who manage a global investment portfolio in excess of USD 11 billion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210709005400/en/

PBIEC operates 16 competition arenas, 2,500 stalls, and provides participants and spectators with a variety of exclusive restaurants, shopping, hospitality areas, and other first-class facilities. PBIEC management will remain intact with Mark Bellissimo continuing as CEO, Michael Stone as President, and David Burton as Chief Operating officer. The GEG initiative will launch major investments in all areas of the facility ensuring that PBIEC will continue to be the pre-eminent sport horse venue in the world with increased exposure in Europe, Asia, and South America. The purchase includes an 11-acre expansion of the Showgrounds. To ensure continuity, the WEP partners required a 50-year deed restriction on the venue that guarantees USEF and FEI sanctioned shows on the property. USEF CEO, Bill Moroney, commented, “As always, we are pleased to see a continued investment in US equestrian sport. This significant commitment to world class facilities, horse and rider welfare, and USEF and FEI competitions further validates the market’s demand, at all levels, for organized sport.” Andreas Helgstrand, co-owner and CEO of GEG added, “The Winter Equestrian Festival and PBIEC are fantastic brands within international equestrian sport. Together, we will strengthen the offering and create a global market leader spreading our passion for equestrian sport and lifestyle to new markets.” Outside of equestrian events the Group is active in other equestrian investments including Helgstrand Dressage, Ludger Beerbaum Stables, Helgstrand Jewellery, and the equestrian apparel and accessories company Kingsland Equestrian. At present, the total revenue of these combined is USD180 million.

GEG will now have event venues in the US, Germany, and Denmark. The partnership will benefit from knowledge sharing and a strengthened positioning of PBIEC within show jumping where Ludger Beerbaum Stables has a unique market position. Furthermore, the partnership enables the Group to leverage PBIEC’s experience and create a European equestrian sports event company. ”Our goal is to enhance equestrian sport by providing superior venues and top sport so riders across the world can live out their passions and dreams. With the acquisition of PBIEC, we now have the perfect setting to do this in the US and with our current expansion of Riesenbeck International in Germany we will have two top professional and attractive show grounds,” says Ludger Beerbaum, four-time Olympic gold medalist in jumping and co-owner of Global Equestrian Group. Bellissimo added, “We are pleased to be collaborating with both Andreas and Ludger, whose passion and commitment to equestrian sport is extraordinary. Opportunities abound to take the sport to a new level.” GEG and WEP are evaluating further investment opportunities in Wellington including a new state-of-the-art Global Dressage Festival showgrounds. Bellissimo will be announcing a comprehensive strategy and a series of investments to elevate Wellington as the World’s premiere equestrian lifestyle destination thus strengthening its international appeal. "The acquisition of PBIEC establishes Global Equestrian Group as a true global market leader in equestrian sports with a strong financial foundation and exciting growth opportunities,” says Kaspar Kristiansen, Managing Director, Waterland Nordic.

About Palm Beach International Equestrian Center
Palm Beach International Equestrian Center (PBIEC) was founded by Mark Bellissimo and Wellington Equestrian Partners in 2006 and has contributed to transforming both equestrian sport and Wellington, Florida’s position as the world’s premiere destination for equestrian enthusiasts. PBIEC arranges 40 weeks of events and operates the Winter Equestrian Festival through its management company, Equestrian Sport Productions. The Winter Equestrian Festival, held over 13 weeks, is the world’s largest and longest-running equestrian sports event with more than 8,000 horses and participants from 50 states and 43 countries. Over 250,000 spectators attend the events. www.pbiec.com

About Global Equestrian Group
Global Equestrian Group is the world’s leading equestrian sports group based on a strategic partnership between internationally acclaimed Helgstrand and Ludger Beerbaum Stables as well as Palm Beach International Equestrian Center and private equity firm Waterland. The Group has 250 full-time employees. Global Equestrian Group has activities in dressage, show jumping and events as well as the jewellery company Helgstrand Jewellery and equestrian apparel and accessories company Kingsland Equestrian as well as other equestrian sports investments. www.globalequestriangroup.com

About Waterland
Waterland is an independent private equity investment group that supports entrepreneurs in realizing their growth ambitions. With substantial financial resources from the firm’s eighth fund of EUR 2.6 billion and committed industry expertise, Waterland enables its portfolio companies to achieve accelerated growth both organically and through acquisitions. To date, Waterland has made investments in over 700 companies. Waterland consistently achieve top tier investment ratings among private equity firms and is the only fund that has consistently been in the top 5 in the HEC/Dow Jones Private Equity Performance Ranking for 10 years. Waterland manages more than EUR 9 billion of investor commitments and has offices in Denmark, the Netherlands, Belgium, Germany, Switzerland, Poland, France, Ireland, and the UK. www.waterland.nu

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye